Note 13 - Segment Information: Segment Revenue Table (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2016	Oct. 31, 2015	Oct. 31, 2016	Oct. 31, 2015
Details
Net revenues - Chinese Medicines	$ 706,115	$ 622,793	$ 1,380,122	$ 1,166,966
Net revenues - Chinese medicine - related party	0	0	0	0
Net revenues - Chinese medicine - Total	706,115	622,793	1,380,122	1,166,966
Net revenues - Stevioside - third party	2,791,223	1,677,631	4,991,995	3,036,135
Net revenues - Stevioside - related party	1,948,631	782,398	3,462,369	3,858,054
Net revenues - Stevioside - Total	4,739,854	2,460,029	8,454,364	6,894,189
Net revenues - Total segment and consolidated revenues	5,445,969	3,082,822	9,834,486	8,061,155
Interest income - Chinese Medicines	20	67	73	136
Interest income - Stevioside	(88,584)	(86,124)	(169,971)	(164,549)
Interest income - Total segment and consolidated interest expense	(88,564)	(86,057)	(169,898)	(164,413)
Depreciation and amortization - Chinese Medicines	72,856	60,548	148,049	152,587
Depreciation and amortization - Stevioside	357,468	367,791	700,999	758,021
Depreciation and amortization - Total segment and consolidated depreciation and amortization	430,324	428,339	849,048	910,608
Loss before taxes and noncontrolling interest - Chinese Medicines	(191,545)	15,587	(149,896)	(8,606)
Loss before taxes and noncontrolling interest - Stevioside	(368,871)	(306,835)	(827,670)	(332,882)
Loss before taxes and noncontrolling interest - Corporate and other	(350,997)	(108,918)	(767,014)	(292,487)
Income (loss) before income taxes - Total segment and consolidated depreciation and amortization	$ (911,413)	$ (400,166)	$ (1,744,580)	$ (633,975)